Research Papers
Publications

Research Papers

Innovative Research from BioAgilytix’s Expert Scientists

Explore the extensive list of research papers to which BioAgilytix’s scientists have contributed:


Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.
Gericke J, Metz M, Ohanyan T, Weller K, Altrichter S, Skov PS, Falkencrone S, Brand J, Kromminga A, Hawro T, Church MK, Maurer MJ. Allergy Clin Immunol. 2017 Mar; 139(3):1059-1061.
Access Here

Establishment of the first WHO Erythropoietin antibody reference panel: Report of an international collaborative study.
Wadhwa M, Mytych DT, Bird C, Barger T, Dougall T, Han H, Rigsby P, Kromminga A, Thorpe R; Participants of the Study. J Immunol Methods. 2016 Aug; 435:32-42.
Access Here

Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: a Phase 1 study.
Curtin F, Vidal V, Bernard C, Kromminga A, Lang AB, Porchet H. MAbs. 2016 Mar 30:0. [Epub ahead of print]
Access Here

B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera.
Homann A, Röckendorf N, Kromminga A, Frey A, Jappe U. J Transl Med. 2015 Oct 29; 13:339. doi: 10.1186/s12967-015-0706-7.
Access Here

Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein.
Curtin F, Perron H, Kromminga A, Porchet H, Lang AB. MAbs. 2015;7(1):265-75. doi: 10.4161/19420862.2014.985021.
Access Here

 

 

Speak to a Scientist







What would you like to discuss?

With whom will we be speaking?






I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.